GILD

Gilead Sciences
Biotechnology · Health Care · as of 2026-11-20
Last close
$168.52
+1.2% on the session
1-year return
+34.9%
+27.0% over six months
Volatility
27.2%
annualized, trailing year
Max drawdown
-21.6%
worst peak to trough, 1y
What the numbers say

Gilead Sciences is a biotechnology name in the health care sector. Over the past year it returned +34.9%, against +15.5% over three months and +7.2% over one. It trades 19.3% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 27.2% is moderate by single-stock standards.

Its worst peak-to-trough decline over the year was -21.6%, and it has traded a median $829M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.19 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#11 of 59
Stronger than 83% of its sector on the momentum profile
Across the whole index#28 of 497

How GILD scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day+1.2%
1 week+0.3%
1 month+7.2%
3 months+15.5%
6 months+27.0%
1 year+34.9%
12-1 momentum+25.8%
Volatility (1y, annualized)27.2%
Max drawdown (1y)-21.6%
Distance vs 200-day average+19.3%
Return per unit of risk1.28
Median daily dollar volume$829M
Free newsletter

Get GILD when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.